Inventor · disambiguated record
Daniel Rueher
Also filed as: RUEHER DANIEL
34 granted patents·10 pending applications·81 citations·filing 2010–2025
96Inventor score
Top patents by PatentIndex Score
44 records- 0196US12209091B2Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancersHOFFMANN LA ROCHE·Filed 2020·Granted Jan 28, 2025·7 cites·30 claims
- 0295US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 0394US11708354B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2020·Granted Jul 25, 2023·3 cites·16 claims
- 0493US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 0592US12344613B2EGFR inhibitor for the treatment of cancerHOFFMANN LA ROCHE·Filed 2020·Granted Jul 1, 2025·3 cites·10 claims
- 0687US10882848B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2019·Granted Jan 5, 2021·3 cites·15 claims
- 0786US11117890B2Substituted isoindole allosteric EGFR inhibitorsHOFFMANN LA ROCHE·Filed 2019·Granted Sep 14, 2021·3 cites·21 claims
- 0886US10189848B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2018·Granted Jan 29, 2019·4 cites·18 claims
- 0986US8420661B2Arylethynyl derivativesGREEN LUKE·Filed 2011·Granted Apr 16, 2013·8 cites·6 claims
- 1084US11242349B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2020·Granted Feb 8, 2022·1 cites·4 claims
- 1183US10065956B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2017·Granted Sep 4, 2018·4 cites·12 claims
- 1283US9695128B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2016·Granted Jul 4, 2017·4 cites·8 claims
- 1383US8513273B2Arylethynyl derivativesHOFFMANN LA ROCHE·Filed 2013·Granted Aug 20, 2013·4 cites·6 claims
- 1482US9725416B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 8, 2017·4 cites·12 claims
- 1582US8618296B2Arylethynyl derivativesHOFFMANN LA ROCHE·Filed 2013·Granted Dec 31, 2013·4 cites·6 claims
- 1681US8716316B2Positive allosteric modulators (PAM)HOFFMANN LA ROCHE·Filed 2013·Granted May 6, 2014·4 cites·14 claims
- 1780US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 1879US9682959B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 20, 2017·2 cites·3 claims
- 1979US8969338B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2012·Granted Mar 3, 2015·4 cites·12 claims
- 2078US8648088B2Ethynyl nitrogen containing heteroaryl pyrazolidin-3-one derivativesJAESCHKE GEORG·Filed 2012·Granted Feb 11, 2014·4 cites·13 claims
- 2178US2025289824A1Egfr inhibitor for the treatment of cancerHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2277US9359301B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2015·Granted Jun 7, 2016·2 cites·10 claims
- 2377US9315498B2Arlethynyl derivativesHOFFMANN LA ROCHE·Filed 2013·Granted Apr 19, 2016·2 cites·8 claims
- 2477US8772300B2Phenyl or pyridinyl-ethynyl derivativesJAESCHKE GEORG·Filed 2012·Granted Jul 8, 2014·4 cites·14 claims
- 2575US9751856B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2017·Granted Sep 5, 2017·1 cites·3 claims
- 2674US12145940B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2022·Granted Nov 19, 2024·0 cites·4 claims
- 2773US8389536B2Positive allosteric modulators (PAM)GREEN LUKE·Filed 2010·Granted Mar 5, 2013·2 cites·13 claims
- 2872US12006323B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2021·Granted Jun 11, 2024·0 cites·16 claims
- 2972US2022135571A1Therapeutic egfr inhibitorsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3065US12479849B2EGFR inhibitors for the treatment of cancerHOFFMANN LA ROCHE·Filed 2020·Granted Nov 25, 2025·0 cites·8 claims
- 3165US2022112199A1Egfr inhibitor for medical useHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3263US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3361US11034699B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2018·Granted Jun 15, 2021·0 cites·16 claims
- 3458US2022315591A1New egfr inhibitorsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3557US2019144458A1Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3651US2022315577A1New egfr inhibitorsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3751US2020308171A1Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moietyHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3851US2020361930A1Bifunctional molecules that degrade egfrHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3949US10011607B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2018·Granted Jul 3, 2018·0 cites·10 claims
- 4048US9676732B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 13, 2017·0 cites·12 claims
- 4144US2016207890A1Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4243US9328070B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2015·Granted May 3, 2016·0 cites·2 claims
- 4343US8530472B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2012·Granted Sep 10, 2013·0 cites·13 claims
- 4442US9227959B2Ethynyl derivativesHOFFMANN LA ROCHE·Filed 2015·Granted Jan 5, 2016·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Daniel Rueher files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →